Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391927 | 0.93 | CNR1 (0.38) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL4393894 | 0.92 | CNR1 (0.38) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL4398426 | 0.90 | CNR1 (0.40) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL4401893 | 0.90 | SCN5A (0.40) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL3552421 | 0.88 | CNR1 (0.39) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL3558221 | 0.87 | CNR1 (0.40) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL3554025 | 0.85 | CNR1 (0.40) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL4394756 | 0.84 | SCN5A (0.39) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL3561545 | 0.82 | CNR1 (0.36) | CNR1CYP2C19CYP2C9CYP3A4PTGS2 | |
| SCHEMBL13593483 | 0.79 | CNR1 (0.41) | CNR1CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2006138657-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CYP2C19 236/4885CYP2C9 311/4885 |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885CYP2C19 236/4885CYP2C9 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.